Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/08—Antiallergic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/08—Vasodilators for multiple indications
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/52—Two oxygen atoms
  • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
  • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
  • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
  • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Definitions

• the present invention is directed to a valuable new form of azithromycin (9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A), viz., a non-hygroscopic dihydrate form thereof.
• Azithromycin is the U.S.A.N. (generic name) for 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A, a broad spectrum antibacterial compound derived from erythromycin A.
• Azithromycin was independently discovered by Bright, U.S. Pat. No. 4,474,768 and Kobrehel et al., U.S. Pat. No. 4,517,359.
• the name “N-methyl-11-aza-10-deoxo-10-dihydroerythromycin A” was employed in these patents. The present more systematic name is based upon the ring expansion and replacement nomenclature of the “IUPAC Nomenclature of Organic Chemistry, 1979 Edition,” Pergamon Press, 1979, pp. 68-70, 459, 500-503.
• azithromycin was obtained as a hygroscopic monohydrate (for details, see Preparation 1 below). Because of its hygroscopic nature, it is most difficult to prepare and maintain this prior monohydrate product in a form having a constant, reproducible water-content. It is particularly difficult to handle during formulation, since at higher relative humidity levels which are generally required to avoid electrostatic problems (e.g., flow rates, dusting with potential for explosion), the monohydrate readily picks up varying amounts of water, the amount depending upon exposure time and the precise value of the relative humidity (see Preparation 1 below). Such problems have been overcome by the present invention of a stable dihydrate which is essentially non-hygroscopic under conditions of relative humidity conducive to formulation of azithromycin.
• the present invention is directed to a valuable new form of azithromycin, viz., a crystalline, non-hygroscopic dihydrate, prepared by crystallization from tetrahydrofuran and an aliphatic (C 5 -C 7 )hydrocarbon in the presence of at least two molar equivalents of water.
• Azithromycin is of the formula
• erythromycin A It is derived from erythromycin A without involvement of asymmetric centers, and so has stereochemistry at each of these centers (*) which is identical with that of erythromycin A.
• the compound Named systematically as an erythromycin A derivative, the compound is called 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin A.
• Azithromycin including the present dihydrate, possess broad-spectrum antibacterial activity useful in the treatment of susceptible bacterial infections in mammals, including man.
• aliphatic (C 5 -C 7 )hydrocarbon refers to lower boiling hydrocarbon solvents, frequently mixtures of particular boiling point ranges such as those generally referred to as “pentane”, “hexane”, “hexanes”, etc., but which may also be substantially pure, e.g., n-hexane, cyclohexane or methylcyclohexane.
• a preferred hydrocarbon solvent is so-called “hexane”, having a boiling point which ranges near that of pure n-hexane.
• Azithromycin prepared according to Bright or Kobrehel et al. (cited above) in amorphous form, or as the monohydrate (which may contain, because of its hygroscopicity, more than one molar equivalent of water) is dissolved in tetrahydrofuran. Since the temperatures required for the initial stages of the present process are not critical, ambient temperatures are generally employed, avoiding the cost of heating and cooling. Furthermore, to maximize yield and minimize solvent, labor and equipment costs, the volume of tetrahydrofuran is kept to a near minimum, e.g., 2 liters of solvent per kilogram of substrate. Any insoluble impurities which may be present at this stage are readily removed by conventional methods of filtration.
• the mixture can be decolorized with activated carbon.
• the highly concentrated mixture can be diluted with a portion of (C 5 -C 7 )hydrocarbon prior to filtration, in order to facilitate handling.
• a drying agent such as MgSO 4 , particularly if hydrocarbon solvent is to be added prior to filtration.
• water is added to the resulting clear solution, in an amount sufficient to bring the total water content to a level corresponding to at least two molar equivalents, generally not exceeding a level of about 3-4 molar equivalents.
• the level of water present in the system is readily monitored by standard Karl Fischer titration.
• the addition of water is followed by the addition of the hydrocarbon solvent (or of more hydrocarbon solvent, if the mixture was previously diluted before filtration), leading to crystallization of the desired dihydrate product.
• This stage of the process can be carried out at ambient temperature (e.g. 17-30° C.), but to facilitate the initial crystallization, is preferably carried at slightly elevated temperature (e.g. 30-40° C.).
• the total volume of hydrocarbon solvent employed is generally at least about four times in volume that of the tetrahydrofuran. Higher volumes of hydrocarbon are satisfactory, but are generally avoided in the interest of minimizing cost.
• the product is recovered by filtration, usually after a period of granulation (e.g., 3-24 hours) at ambient temperature.
• the product is usually vacuum dried of organic solvents (at 20-40° C., conveniently at ambient temperature).
• the volatiles and water-content are generally monitored during drying, such that the level of tetrahydrofuran and hydrocarbon will generally fall below 0.25% and the water content will be within 0.3% of theory (4.6%).
• Azithromycin dihydrate is formulated and administered in the treatment of susceptible bacterial infections in man according to methods and in amounts previously detailed by Bright, U.S. Pat. No. 4,474,768, cited above and hereby incorporated by reference.
• the mixture was cooled to ambient temperature, diluted with 400 ml H 2 O and adjusted to pH 10.5 with 50% NaOH.
• the aqueous layer was separated and extracted 2 ⁇ 100 ml with fresh CHCl 3 .
• the organic layers were combined, stripped in vacuo to 350 ml, twice diluted with 450 ml of ethanol and restripped to 350 ml, and finally diluted with 1000 ml H 2 O over a 1 hour period, pausing for 15 minutes as a slurry began to develop after the addition of about 250 ml of H 2 O.
• Title product was recovered by filtration and dried in air at 50° C.
• a sample of the monohydrate (having a water content of 3.2%) was maintained at 18% relative humidity for 14 days.
• the sample lost water over the first 24 hours to yield monohydrate having the theoretical water content (2.35%).
• the water content then remained substantially constant over 14 days, a value of 2.26% being recorded at 14 days.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• General Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Cardiology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Genetics & Genomics (AREA)
• Heart & Thoracic Surgery (AREA)
• Biotechnology (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Vascular Medicine (AREA)
• Urology & Nephrology (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Saccharide Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (1)

Applications Claiming Priority (4)

Related Parent Applications (1)

Publications (1)

Family

ID=22202456

Family Applications (1)

Country Status (45)

Cited By (39)

Families Citing this family (37)

Citations (7)

Family Cites Families (2)

• 1987
  • 1987-07-09 MX MX1221388A patent/MX12213A/es unknown
  • 1987-07-09 UA UA93004522A patent/UA27040C2/uk unknown
  • 1987-07-09 RO RO143593A patent/RO107257B1/ro unknown
  • 1987-07-09 RU SU874742955A patent/RU2066324C1/ru active
  • 1987-07-09 WO PCT/US1987/001612 patent/WO1989000576A1/en active IP Right Grant
• 1988
  • 1988-05-11 IN IN418/DEL/88A patent/IN168879B/en unknown
  • 1988-06-15 AP APAP/P/1988/000093A patent/AP44A/en active
  • 1988-06-28 EP EP88305921A patent/EP0298650B1/en not_active Expired - Lifetime
  • 1988-06-28 DE DE8888305921T patent/DE3868296D1/de not_active Expired - Lifetime
  • 1988-06-28 ES ES198888305921T patent/ES2038756T3/es not_active Expired - Lifetime
  • 1988-06-28 AT AT88305921T patent/ATE72446T1/de not_active IP Right Cessation
  • 1988-07-04 IL IL86979A patent/IL86979A/xx not_active IP Right Cessation
  • 1988-07-05 MY MYPI88000744A patent/MY103744A/en unknown
  • 1988-07-05 BG BG84783A patent/BG47348A3/xx unknown
  • 1988-07-06 CS CS884896A patent/CS272241B2/cs not_active IP Right Cessation
  • 1988-07-06 JP JP63168637A patent/JPH0631300B2/ja not_active Expired - Lifetime
  • 1988-07-07 DD DD88317672A patent/DD271705A5/de unknown
  • 1988-07-07 PH PH37189A patent/PH30953A/en unknown
  • 1988-07-07 EG EG376/88A patent/EG18527A/xx active
  • 1988-07-07 CA CA000571381A patent/CA1314876C/en not_active Expired - Lifetime
  • 1988-07-07 AR AR88311356A patent/AR243532A1/es active
  • 1988-07-07 PL PL1988273590A patent/PL157145B1/pl unknown
  • 1988-07-07 PT PT87933A patent/PT87933B/pt not_active IP Right Cessation
  • 1988-07-07 IS IS3370A patent/IS1540B/is unknown
  • 1988-07-08 SI SI8811325A patent/SI8811325A8/sl unknown
  • 1988-07-08 IE IE210888A patent/IE60354B1/en not_active IP Right Cessation
  • 1988-07-08 KR KR1019880008463A patent/KR900006218B1/ko not_active IP Right Cessation
  • 1988-07-08 NZ NZ225338A patent/NZ225338A/xx unknown
  • 1988-07-08 ZA ZA884925A patent/ZA884925B/xx unknown
  • 1988-07-08 OA OA59384A patent/OA08743A/xx unknown
  • 1988-07-08 CN CN88104331A patent/CN1016785B/zh not_active Expired
  • 1988-07-08 YU YU1325/88A patent/YU45075B/xx unknown
  • 1988-07-08 DK DK198803806A patent/DK172573B1/da not_active IP Right Cessation
  • 1988-07-08 AU AU18839/88A patent/AU604553B2/en not_active Expired
  • 1988-07-11 MA MA21565A patent/MA21323A1/fr unknown
• 1990
  • 1990-01-08 FI FI900087A patent/FI91263C/fi not_active IP Right Cessation
  • 1990-01-08 NO NO90900077A patent/NO171556C/no not_active IP Right Cessation
• 1992
  • 1992-02-06 GR GR920400067T patent/GR3003737T3/el unknown
  • 1992-12-21 US US07/994,040 patent/US6268489B1/en not_active Expired - Lifetime
• 1993
  • 1993-11-17 LV LVP-93-1240A patent/LV10624B/xx unknown
• 1994
  • 1994-02-22 SG SG27794A patent/SG27794G/en unknown
  • 1994-11-17 HK HK127594A patent/HK127594A/xx not_active IP Right Cessation
• 1995
  • 1995-06-30 HU HU95P/P00738P patent/HU211862A9/hu unknown
  • 1995-10-20 CY CY177695A patent/CY1776A/xx unknown
• 1998
  • 1998-03-30 BA BA980213A patent/BA98213B1/bs active

Patent Citations (7)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events